Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 24 January 2025 12:00 AM EOD	Adani-Ports1093.90	Asian-Paints2261.80	Axis-Bank948.30	Bajaj-Finance7439.25	Bajaj-Finserv1728.50	Bharti-Airtel1643.90	HCL-Technologies1793.55	HDFC-Bank1649.55	Hind-Unilever2368.90	ICICI-Bank1209.45	IndusInd-Bank950.45	Infosys1875.15	ITC441.50	Kotak-Mah-Bank1886.40	Larsen-and-Toubro3457.75	M-and-M2801.00	Maruti-Suzuki11972.80	Nestle-India2209.35	NTPC323.70	Power-Grid-Corpn295.75	Reliance-Industr1245.90	St-Bk-of-India744.35	Sun-PharmaInds1821.90	Tata-Motors733.90	Tata-Steel130.00	TCS4151.30	Tech-Mahindra1722.25	Titan-Company3398.50	UltraTech-Cem11287.65	Zomato-Ltd215.80
15 mins delay SENSEX 76,190.46 [-329.92]	-9.95 -0.90%	-14.65 -0.64%	-3.35 -0.35%	-5.40 -0.07%	-17.25 -0.99%	7.75 0.47%	-12.30 -0.68%	-15.25 -0.92%	46.00 1.98%	7.00 0.58%	-20.45 -2.11%	10.35 0.56%	1.30 0.30%	-8.20 -0.43%	-45.95 -1.31%	-84.35 -2.92%	-73.50 -0.61%	13.75 0.63%	0.05 0.02%	1.45 0.49%	-17.95 -1.42%	-1.60 -0.21%	-12.15 -0.66%	-18.65 -2.48%	-0.50 -0.38%	5.60 0.14%	9.35 0.55%	-1.70 -0.05%	-135.05 -1.18%	-6.10 -2.75%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Auro Pharma arm gets USFDA nod for Pazopanib tabs

05-Dec-24 15:41Hrs IST

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, of Novartis Pharmaceuticals Corporation.

Pazopanib Tablets, is indicated for the treatment of adults with advanced renal cell carcinoma (RCC), and advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

The product is expected to be launched in Q4 FY25. The approved product has an estimated market size of $106 million for the twelve months ending October 2024, according to IQVIA.

This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24.

Shares of Aurobindo Pharma declined 0.98% to Rs 1,245.70 on the BSE.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise